Acer Therapeutics Inc (NASDAQ:ACER) Sellers Rose By 272.87% Their Shorts

Change of 272.87% for Acer Therapeutics Inc (NASDAQ:ACER)’s shares shorted was noted. FINRA published in December ACER’s total 92,100 shares shorted. That’s 272.87% up from 24,700 shares. With Average volume 63,900, ACER’s former position will take 1 days to restore.

ACER is hitting $20.02 during the last trading session, after decreased 4.67%.Currently Acer Therapeutics Inc. is uptrending after 199.76% change in last December 8, 2017. ACER has also 29,250 shares volume. ACER outperformed by 184.14% the S&P 500.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs.The firm is worth $201.26 million. The firm offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease .Currently it has negative earnings. It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD).

For more Acer Therapeutics Inc. (NASDAQ:ACER) news announced briefly go to: Nasdaq.com, Seekingalpha.com, Fool.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “NVIDIA (NVDA) Q1 Earnings & Revenues Top Estimates, Grow Y/Y – Nasdaq” announced on May 11, 2018, “Did Shares Of Advanced Micro Devices Deserve A ‘Sell’ Rating? – Seeking Alpha” on October 22, 2018, “Why JD.com Stock Is Down 53% This Year – The Motley Fool” with a publish date: November 24, 2018, “AMD: Unstoppable – Seeking Alpha” and the last “Agency for the Cooperation of Energy Regulators (ACER) continues to use Nasdaq’s SMARTS for Pan-European Market Monitoring of EU Wholesale Energy Markets – GlobeNewswire” with publication date: January 22, 2018.

Acer Therapeutics Inc. (NASDAQ:ACER) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.